
|Videos|November 10, 2022
Dr. Hafron explains the benefits of Jelmyto in UTUC since its approval
Author(s)Urology Times staff
"We're seeing that it's beneficial to the patient—it’s easier, they don't require a general anesthetic, and we don't have to bring him to the hospital," says Dr. Hafron.
Advertisement
During the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA reports increased demand, supply efforts for estradiol transdermal patches
2
The UroOnc Minute: Perioperative Intravesical Chemotherapy at Nephroureterectomy, With Surena F. Matin, MD, FACS
3
What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed
4
NeoBLAST trial tests active surveillance after complete response in MIBC
5











